Who are EBR/GZR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): EBR/GZR (elbasvir/grazoprevir), Daclatasvir plus Asunaprevir, Elbasvir/Grazoprevir Fixed Dose Combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ebr-gzr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

EBR/GZR — Competitive Intelligence Brief

EBR/GZR (EBR/GZR) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor). Area: Virology / Hepatology.

marketed Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor) Hepatitis C virus NS5A protein and NS3/4A serine protease Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

EBR/GZR (EBR/GZR) — Dallas VA Medical Center. EBR/GZR is a fixed-dose combination of elbasvir and grazoprevir that inhibits hepatitis C virus NS5A and NS3/4A proteases to block viral replication.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EBR/GZR TARGET	EBR/GZR	Dallas VA Medical Center	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	Hepatitis C virus NS5A protein and NS3/4A serine protease
EBR/GZR (elbasvir/grazoprevir)	EBR/GZR (elbasvir/grazoprevir)	University of Florida	marketed	Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor	Hepatitis C virus NS5A protein and NS3/4A serine protease
Daclatasvir plus Asunaprevir	Daclatasvir plus Asunaprevir	Myeong Jun Song	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease
Elbasvir/Grazoprevir Fixed Dose Combination	Elbasvir/Grazoprevir Fixed Dose Combination	University Hospital, Clermont-Ferrand	phase 3	HCV direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor) class)

Dallas VA Medical Center · 1 drug in this class
Myeong Jun Song · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EBR/GZR — Competitive Intelligence Brief. https://druglandscape.com/ci/ebr-gzr. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab